GEMS | Jotup

BAE Systems selected to build atmospheric composition instrument for NOAA's GeoXO constellation

Retrieved on:

Wednesday, May 1, 2024

BROOMFIELD, Colo., May 1, 2024 /PRNewswire/ -- BAE Systems (LON: BA) was selected by NASA to develop the Atmospheric Composition instrument (ACX) that will fly on the National Oceanic and Atmospheric Administration's (NOAA) Geostationary Extended Observations (GeoXO) satellite constellation.

Key Points:

BROOMFIELD, Colo., May 1, 2024 /PRNewswire/ -- BAE Systems (LON: BA) was selected by NASA to develop the Atmospheric Composition instrument (ACX) that will fly on the National Oceanic and Atmospheric Administration's (NOAA) Geostationary Extended Observations (GeoXO) satellite constellation.
However, GeoXO will also provide novel, high-priority capabilities such as atmospheric composition, infrared sounding and ocean color observations to enhance forecasts and science benefits.
The ACX instrument builds on BAE Systems experience developing innovative atmospheric monitoring capabilities.
In addition to ACX, BAE Systems was also selected to build the GeoXO Sounder (GXS) instrument, which will measure atmospheric moisture, winds, and temperature to enhance weather prediction models and short-term severe weather forecasting among other applications.

Centurion Service Group to auction all assets following the closure of St. Margaret’s Health - Spring Valley f/k/a St. Margaret’s Hospital in Spring Valley, IL

Retrieved on:

Monday, April 15, 2024

Centurion, Sale, Bankruptcy, Instrument, Hospital, CST, GEMS, CFD, Radiology, United States bankruptcy court, Medicine, Auction

23-11641, assets of St. Margaret’s Health - Spring Valley.

Key Points:

23-11641, assets of St. Margaret’s Health - Spring Valley.
Medical assets will be sold on a 2-day timed online auction scheduled for Wednesday, April 24, at 9 a.m. CST and Thursday, April 25, at 9 a.m. CST.
All non-medical assets, including vehicles, fully-equipped kitchens, furniture, and more, will be sold via online auction on Thursday, May 2, at 10 a.m. CST.
Parties interested in bidding and purchasing items from the closure of St. Margaret’s Health – Spring Valley f/k/a St. Margaret’s Hospital should register at centurionservice.com/closure-auctions .

Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing

Retrieved on:

Thursday, May 2, 2024

Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.

Key Points:

Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.
The hTSC platform is the earliest ethically sourced pluripotent stem cells that are naive, powerful, lively and have high plasticity.
These limitations compound and can cause cell functionality compromises and performance issues downstream, given the lack of consistency in engineered cells and inefficient scale-up.
Mekonos recognizes there is a better way, and we are rising to the challenge,” Narasimha added.

Golub Capital Announces $2 Billion Final Close for its Sixth Credit Opportunities Fund

Retrieved on:

Tuesday, April 30, 2024

Asset Management, Professional Services, Finance, GEMS, NAV, CLO, Golub Capital, Capital, Financial services

Golub Capital today announced the final close of its sixth credit opportunities fund, GEMS Fund 6, L.P. (“the Fund” or “Fund 6”), with $2 billion of investable capital.

Key Points:

Golub Capital today announced the final close of its sixth credit opportunities fund, GEMS Fund 6, L.P. (“the Fund” or “Fund 6”), with $2 billion of investable capital.
Fund 6 is the largest Golub Capital Credit Opportunities fund to-date.
“We have a proven track record in Credit Opportunities with five successful predecessor funds over the past 17 years,” said David Golub, President of Golub Capital.
With a dedicated strategy since 2007, Golub Capital Credit Opportunities leverages the full breadth of the Golub Capital platform’s capital markets, leveraged finance, sales and trading, broadly syndicated loan and direct lending expertise including the ability to identify mispriced value while maintaining a relentless focus on downside protection.

Fierce Medtech Names Genesis Therapeutics a “Fierce 15” Company of 2023

Retrieved on:

Wednesday, March 6, 2024

Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.

Key Points:

Genesis Therapeutics , a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies.
"We are honored to receive this recognition from Fierce and be included among true innovators in AI and life sciences," said Evan Feinberg, Ph.D., co-founder and CEO of Genesis.
Being named a Fierce 15 company is testament that our team is yielding tangible results in developing AI technologies that generate transformative drugs for patients."
“These companies exemplify the ability of the life sciences industry to turn cutting-edge ideas into meaningful outcomes.”

Context Labs recognized by Gartner® in 2023 Market Guide for Gas Emissions Management

Retrieved on:

Tuesday, December 5, 2023

CAMBRIDGE, Mass. and AMSTERDAM, Dec. 5, 2023 /PRNewswire-PRWeb/ -- Context Labs, a leading enterprise data fabric-based climate analytics company, in Cambridge, MA, and Amsterdam, has been covered across three Gartner publications: as a Representative Vendor in the Market Guide for Gas Emissions Management (9 October 2023) report, as a Sample Vendor in the Hype Cycle™ for Blockchain and Web3 (2 August 2023), and in the Hype Cycle™ for Open-Source Software (21 July 2023).

Key Points:

Coverage supports COP28 goal for emissions reduction this decade Gartner covers Context Labs in 2023 reports-Market Guide for Gas Emissions Management, Blockchain and Web3, 2023, and Open-Source Software
CAMBRIDGE, Mass.
Context Labs continues to push and define the Gas Emissions Management Solutions (GEMS) industry by offering industry proven emission tracking capabilities — data fabric, emissions visualizations, carbon accounting, modeling, and reporting.
Additionally, Context Labs is bridging the gap between Web2 and Web3 with advances in Web 2.5 and authenticated provenance technologies.
"To us, it is energizing and affirming to receive this support and recognition from Gartner analysts for the work that Context Labs is achieving with our industry partners," shared Dan Harple, CEO of Context Labs.

Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability

Retrieved on:

Thursday, October 26, 2023

Science, AAV, DCAS, Facioscapulohumeral muscular dystrophy, Biotechnology, FSHD, PAMS, Congress, Dicarboxylic acid, Cell, GEMS, Gene, ESGCT, European Society of Gene and Cell Therapy, Patient, Gene expression, SAN, Vaccine, Cas

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.

Key Points:

These data are being presented at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress taking place October 24-27, 2023, in Brussels, Belgium.
Among the data being presented are new details on Epic’s in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas protein known to work in human cells.
In new data at ESGCT, Epic reports that these three Cas effectors also display greater flexibility in the genetic sequences, called PAMs, that they can target.
“These data highlight why GEMS is an unparalleled therapeutic platform, and how our team’s unique expertise is expanding the state of the science in epigenetic editing every day.”

Cadmus Awarded Multi-year, USAID ES3 Contract With $93 Million Total Ceiling

Retrieved on:

Thursday, October 12, 2023

Winning ES3 highlights Cadmus’ ongoing role as the Agency’s leading safeguards support contractor.

Key Points:

Winning ES3 highlights Cadmus’ ongoing role as the Agency’s leading safeguards support contractor.
This single-award, Agency-wide contract supports a consistent, quality approach to safeguards implementation across USAID, including implementing partner training and environmental officer backstopping support.
Cadmus will deliver via its dedicated in-house USAID safeguards support team, its in-house and global network of subject matter experts, and by bringing to USAID the full capabilities of its small business-centered ES3 team.
“We are incredibly proud that the Cadmus team has been awarded this contract to continue our environmental and social safeguards support for USAID,” said President and CEO Ian Kline.

Milltrust International launches East West Private Wealth, a global sustainability-focused multi-family office

Retrieved on:

Wednesday, October 4, 2023

LONDON and SINGAPORE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Milltrust International, an award-winning investment manager co-headquartered in London and Singapore, today announces the launch of East West Private Wealth (“EWPW”), a global sustainability-focused multi-family office with a focus on protecting and investing assets for families who prioritise sustainability and impact.

Key Points:

LONDON and SINGAPORE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Milltrust International, an award-winning investment manager co-headquartered in London and Singapore, today announces the launch of East West Private Wealth (“EWPW”), a global sustainability-focused multi-family office with a focus on protecting and investing assets for families who prioritise sustainability and impact.
Too often it’s a homogenised offering trying to squeeze clients into one of a number of model portfolios.
Finally, in Singapore, long-standing Milltrust director and veteran fund manager, Dennis See leads EWPW’s affiliate, First Estate Capital Management.
Dennis founded PointWorth Management, the first exempt fund manager in Singapore, and held leadership roles at Indosuez and Chemical Bank (now JP Morgan) in Singapore.

Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators

Retrieved on:

Thursday, September 14, 2023

Biotechnology, Protein engineering, DCAS, GEMS, Discovery, Therapy, Gene expression, BioRxiv, SAN, Engineering, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced data supporting the breakthrough potential of its Gene Expression Modulation System (GEMS) platform for epigenetic engineering. In two preprint studies posted on bioRxiv, the company reported the discovery of exceptionally durable, hypercompact gene activators, and the training of a machine learning model to generate additional synthetic activators. Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced data supporting the breakthrough potential of its Gene Expression Modulation System (GEMS) platform for epigenetic engineering. In two preprint studies posted on bioRxiv, the company reported the discovery of exceptionally durable, hypercompact gene activators, and the training of a machine learning model to generate additional synthetic activators.

Key Points:

In two preprint studies posted on bioRxiv, the company reported the discovery of exceptionally durable, hypercompact gene activators, and the training of a machine learning model to generate additional synthetic activators.
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced data supporting the breakthrough potential of its Gene Expression Modulation System (GEMS) platform for epigenetic engineering.
In two preprint studies posted on bioRxiv, the company reported the discovery of exceptionally durable, hypercompact gene activators, and the training of a machine learning model to generate additional synthetic activators.
Ultimately, Epic’s team created activators that induce the most durable and mitotically stable gene activation reported to date.